RepRegen
RepRegen develops a hard tissue repair and regeneration platform to be used by orthopedic product manufacturers and surgeons.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| $1.6m | Early VC | |
| Total Funding | 000k | ||
Related Content
RepRegen Ltd., originating as BioCeramic Therapeutics, was established in London, United Kingdom, in 2006 by founders Molly Stevens and Daniel Green. The company operated as a medical device firm centered on 'smart biomaterials', emerging as a spin-out from the Imperial Innovations incubator at Imperial College London. Its core focus was on proprietary repair and regeneration technology platforms engineered to heal and regrow both hard tissues, like bone, and soft tissues, such as cartilage.
The company's primary technology involved the use of patented Strontium-based bioactive glass, a type of 'smart' bioceramic. This material was designed to promote osteoblast cell activity and proliferation, thereby enhancing the speed and quality of tissue repair. A key materials science development was the integration of Strontium, which was shown in in-vitro studies to have a positive effect on bone cell activity and mineralization by boosting the performance of the bioceramics. The initial product developed from this platform was StronBone Bone Graft Substitute, which received a CE mark and was intended for use by orthopaedic product manufacturers and surgeons in applications such as orthopaedic trauma, spine, and craniomaxillofacial procedures.
RepRegen's business strategy was multifaceted, aiming to generate early revenue through a combination of out-licensing its platform technologies and pursuing the direct market introduction of its own products. This dual approach was designed to provide commercial validation while supporting further development. In November 2010, the company secured $1.6 million in a Series A funding round from investors including Imperial Innovations and Longbow Capital. Despite its early scientific and commercial activities, the company is now considered deadpooled.
Keywords: medical devices, smart biomaterials, tissue regeneration, hard-tissue repair, soft-tissue repair, bioactive glass, StronBone, bone graft substitute, orthopaedics, craniomaxillofacial, bioceramics, Strontium-based platform, tissue engineering, regenerative medicine, Imperial College spin-out, Molly Stevens, Daniel Green, preclinical studies, in-vivo data, CE-marked device